Zanubrutinib

(Brukinsa)

Zanubrutinib

Drug updated on 11/14/2023

Dosage FormCapsule (oral: 80 mg)
Drug ClassKinase inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
  • For the treatment of adult patients with Waldenström’s macroglobulinemia (WM).
  • For the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.
  • For the treatment of adult patients with Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)